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FDA = United States Food and Drug Administration; GP = glycoprotein; MI = myocardial infarction; PAES = Parodi Anti-Emboli System; 
US = United States.
GUARD = Saphenous Vein Graft Intervention using AngioGuard for Reduction of Distal Embolization trial; SAFE = Saphenous Vein Graft Angio-
plasty Free of Emboli study; SAFER = Saphenous Vein Graft Angioplasty Free of Emboli, Randomized trial; SAPPHIRE = The Study of Angioplasty
with Protection in Patients at High Risk for Endarterectomy; TIMI = Thrombolysis in Myocardial Infarction.
Current Controlled Trials in Cardiovascular Medicine    December 2001 Vol 2 No 6 Fasseas et al.
Distal embolization of particulate matter, including plaque
debris and thrombus, complicate percutaneous coronary and
peripheral interventions more often than had been recognized
until recently. This often results in diminished blood flow to
the distal vascular bed and is associated with periprocedural
end-organ ischemia and infarction, as demonstrated by perfu-
sion defects and serum cardiac enzyme elevation [1,2].
Periprocedural myocardial infarction (MI) is associated with a
worse prognosis, particularly when it is large, which is most
clearly demonstrated in saphenous vein bypass graft interven-
tions. This was demonstrated by Hong et al. who studied
1056 consecutive patients with angiographically successful
percutaneous coronary intervention of 1693 SVG lesions [3].
One-year mortality was significantly increased in patients with
periprocedural creatine kinase-MB elevation, even among
patients without any apparent procedure or in-hospital com-
plication.
Distal embolization of large particles at the time of balloon
inflation or stent deployment may obstruct large, epicardial
vessels, but the scope of the problem includes microvascular
obstruction due to very small particles, as little as 15–100
microns, that may result in microinfarcts and left ventricular
dysfunction [4]. It is likely that mechanical microvascular
obstruction is commonly aggravated by secondary spasm
and edema due to release of humoral agonists by platelets,
and endothelial injury and dysfunction. Limited therapeutic
success has been reported from observational studies involv-
ing the use of calcium channel blockers, adenosine, and
sodium nitroprusside [5]. However, the success of these
medical interventions is most commonly defined by angio-
graphic resolution of the “no-reflow” phenomenon (an acute
reduction in coronary flow less than Thrombolysis in Myocar-
dial Infarction [TIMI] 2 in the absence of dissection, thrombus,
spasm, or high-grade residual stenosis at the original target
lesion). A beneficial effect on hard clinical endpoints has
been more difficult to prove. 
Glycoprotein IIb/IIIa inhibitors and
percutaneous coronary intervention
Glycoprotein (GP) IIb/IIIa inhibitors reduce not only proce-
dural infarctions, but also major adverse clinical events in
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Abstract
Distal embolization of particulate matter complicates percutaneous coronary and peripheral
interventions more often than had been recognized until recently. A number of distal protection devices
are under development. The PercuSurge GuardWire™ is a balloon occlusion thrombectomy device
approved by the United States Food and Drug Administration for saphenous vein graft intervention. A
number of filter devices utilize an expandable filter mounted on the angioplasty guidewire to facilitate
entrapment of particles and safe removal. The Parodi Anti-Emboli System™ is an example of a catheter
occlusion device that establishes protection by reversing blood flow in the target vessel.
Keywords angioplasty, distal protection device, procedural myocardial infarctionAvailable online http://cvm.controlled-trials.com/content/2/6/286
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
s
e
a
r
c
h
patients undergoing percutaneous coronary intervention. The
benefit is thought to be, in part, due to a reduction in the inci-
dence of ischemic complications, which is likely to be sec-
ondary to prevention of platelet aggregation, thrombus
formation, and distal embolization, in native coronary arteries
[6]. These benefits, however, have been apparent in subset
analyses of clinical trials, or in observational studies designed
to specifically assess their efficacy in saphenous vein graft
interventions. Despite suggestion of benefit as measured by
surrogate angiographic endpoints, there is no evidence of a
consistent and sustained meaningful clinical benefit [7,8].
The likely explanation for this apparent lack of benefit in vein
graft interventions, when GP IIb/IIIa inhibitors clearly reduce
procedural infarctions by approximately 50%, is the differ-
ence in the composition of the embolic material. Distal
embolization during saphenous vein graft intervention is pre-
dominantly due to soft acellular atheromatous material typi-
cally found under the fibrous cap (cholesterol clefts, lipid-rich
macrophages, and fibrin material) that occurs in >10% of
interventions on vein grafts that are more than three years old
[9]. Independent predictors of distal embolization include
diffuse degeneration and large plaque volume rather than
thrombus, and angioscopy studies have found that vein graft
friability, rather than thrombus, was a stronger predictor of
distal embolization and ‘no-reflow’ [9,10]. The relative contri-
bution of platelet aggregates or atheromatous material to
distal embolization and vessel occlusion in native coronary
arteries is unclear. Despite these aforementioned beneficial
effects of aggressive platelet inhibition during percutaneous
coronary intervention, however, further reductions in distal
embolization remains an important goal, particularly in the
acute coronary syndromes.
Percutaneous carotid interventions
Percutaneous carotid interventions are frequently complicated
by embolization [11]. Jordan et al. and others have demon-
strated that there is Doppler evidence of microembolization
during almost all carotid stenting procedures [12]. The precise
clinical significance of this phenomenon remains unclear,
since the brain appears to have a surprising tolerance for
microembolization in the acute setting. No one has yet linked
these emboli to adverse clinical events. However, even small
plaque fragments less than 200 microns may cause neuronal
ischemia at later time points, and periprocedural microemboli
may be responsible for both stroke and more subtle neuro-
logic dysfunction in late follow-up [13,14]. Carotid angioplasty
and stenting is associated with a perioperative stroke rate
exceeding 3% in most series, largely due to emboli. Addition-
ally, this embolic complication continues to limit the applicabil-
ity of percutaneous revascularization in patients who are
suitable for surgical carotid endarterectomy [15].
Balloon occlusion devices: PercuSurge
GuardWire
A number of distal protection devices that aim to reduce or
eliminate distal embolization during percutaneous coronary
and carotid interventions are under development (Table 1).
Only one such device has already been approved for use by
the United States Food and Drug Administration (FDA). The
PercuSurge GuardWire (Medtronic, Santa Rosa, CA, USA) is
an occlusion thrombectomy device that consists of a wire
containing a central lumen that communicates with a low-
pressure distal occlusion balloon incorporated into the tip
(Fig. 1). The wire serves as both the angioplasty guidewire
and provides protection from distal embolization. An inflation
device allows controlled expansion and sizing of the occlu-
sion balloon in the treated vessel. An aspiration catheter is
used to remove the debris from the treated vessel before the
balloon is deflated and antegrade flow in the treated vessel is
restored.
The Saphenous Vein Graft Angioplasty Free of Emboli (SAFE)
study evaluated the safety and feasibility of this device [16].
Initial encouraging results in the European and Canadian reg-
istries were confirmed in the Saphenous Vein Graft Angio-
plasty Free of Emboli, Randomized (SAFER) trial conducted in
the United States (US) [17]. The SAFER trial was conducted
at 47 sites and enrolled 659 patients undergoing saphenous
vein graft percutaneous coronary intervention. Inclusion criteria
were stenoses of 50–99% in saphenous vein grafts 3–6 mm
in diameter, more than 5 mm from the ostium and 20 mm from
Table 1
Distal protection devices that are available or under development
Device type Device name Manufacturer
Balloon occlusion devices PercuSurge GuardWire Medtronic, Santa Rosa, CA, USA
Filter devices AngioGuard Cordis Corp., Minneapolis, MN, USA
FilterWire EX Boston Scientific Corp., Natick, MA, USA
Mednova Neuroshield Mednova Inc., Galway, Ireland
AccuNet Guidant Corp., Indianapolis, IN, USA
Catheter occlusion devices Parodi Anti-Emboli System ArteriA Medical Science, Inc., San Francisco, CA, USACurrent Controlled Trials in Cardiovascular Medicine    December 2001 Vol 2 No 6 Fasseas et al.
the distal anastamosis, and at least TIMI 1 flow at baseline.
Exclusion criteria included acute MI, ejection fraction <25%,
creatinine >2.5 mg/dL (unless on hemodialysis), and planned
use of an atherectomy device. The primary endpoint was the
occurrence of major adverse clinical events at 30 days, includ-
ing death, MI, emergency bypass surgery, and repeat target
vessel revascularization.
Pre-specified secondary endpoints were the frequency with
which TIMI 3 flow was achieved, and clinically apparent no-
flow occurred. The GuardWire was superior to ‘standard
care’ (Figs 2 and 3). There was a 50% relative reduction in
cumulative 30-day major adverse cardiac events (17.8% to
9.0%, P = 0.001), a 68% relative reduction in mortality (2.8%
to 0.9%, P = 0.086), and a 49% relative reduction in MI
(17.3% to 8.8%, P = 0.003). The trial was stopped early by
the data safety monitoring board, and the manufacturer
promptly secured FDA approval.
Interestingly, although GP IIb/IIIa inhibitors were used in >60%
of all patients, predominantly before intervention, major adverse
clinical events were more common amongst those receiving
the drug. Since this was a non randomized, retrospective analy-
sis, no conclusions about a potentially beneficial (or deleteri-
ous) affect can be made. However, it is apparent that the
reduction in major adverse clinical events in the GuardWire
arm was independent of the use of GP IIb/IIIa inhibitors.
Similarly, the feasibility and safety of carotid angioplasty and
stenting using the PercuSurge GuardWire system has been
determined [10]. Technical success was reported in a series
of 48 high-risk patients (39 men, mean age 69.1 ± 8 years)
with 53 internal carotid artery stenoses. Mean cerebral flow
occlusion time was 346 ± 153 seconds during predilation
and 303 ± 143 seconds during stent placement. One imme-
diate neurological complication (transient amaurosis fugax)
was documented in a patient who had a surgical anastamosis
between the external and internal carotid arteries.
Filter Devices
AngioGuard™
A second ‘class’ of distal protection devices under develop-
ment and currently undergoing clinical investigation are the
filter devices. AngioGuard (Cordis Corp., Minneapolis, MN,
USA) is an example of such a device that has recently
Figure 1
The PercuSurge GuardWire balloon occlusion device and export
catheter.
Figure 2
Major adverse cardiac events that had occurred by 30 days in the
SAFER trial. All MI, all myocardial infarction; CABG, coronary artery
bypass graft surgery; MACE, major adverse cardiac events at 30 days;
non-Q MI, non-Q-wave myocardial infarction; Q-MI, Q-wave myocardial
infarction; TLR, target lumen revascularization. *P = 0.001, 
**P = 0.003, †P = not significant.
Figure 3
The frequency of secondary endpoints in the SAFER trial. Closure
refers to abrupt vessel closure. TIMI, Thrombolysis in Myocardial
Infarction. *P = 0.004, **P = 0.005, †P = not significant.received approval for marketing in Europe. AngioGuard’s
technology incorporates an angioplasty guidewire with a filter
that expands to 6 mm and is placed distal to the target lesion
to capture and retrieve embolic debris (Fig. 4). At the end of
the procedure, the filter is collapsed, trapping the particulate
matter and facilitating removal from the artery.
The AngioGuard filter has multiple, 100 micron, laser-drilled
holes that allow perfusion during device deployment. It has
been proposed that this is a major advantage of filter devices.
In contrast, the balloon occlusion devices result in complete
cessation of antegrade flow for as long as it takes to treat the
vessel and aspirate the debris (typically 2–3 minutes in the
hands of experienced operators) [9,15]. This is a critical clini-
cal consideration in patients with reduced left ventricular func-
tion or in patients in whom the treated artery supplies a large
amount of myocardium. Conversely, it has been proposed that
incomplete vessel occlusion with the filter devices allows
passage of debris through the holes of the filter devices.
Indeed, analysis of debris retrieved by the balloon occlusion
thrombectomy device in the SAFE trial device found that 80%
of the particulate matter was less than 100 microns in diame-
ter. The clinical significance of such small embolic particles is
unclear, and difficult to resolve since the completeness of
debris entrapment by any distal protection device is impossi-
ble to determine in clinical practice.
The initial experience with the AngioGuard filter device is
promising. A phase I trial in 33 consecutive lesions (in 31
patients) of the internal carotid artery documented successful
deployment of the filter in 82% of the lesions. Debris that
might have been expected to result in distal vessel occlusion
was collected in 80% of cases. This technology is currently
under investigation in the US for both carotid and coronary
percutaneous interventions in appropriately sized trials.
The Study of Angioplasty with Protection in Patients at High
Risk for Endarterectomy (SAPPHIRE) is examining the bene-
fits of the AngioGuard device among 720 patients undergo-
ing carotid artery stenting in a randomized trial versus
‘standard care’ (no distal protection device) [18]. The Saphe-
nous Vein Graft Intervention using AngioGuard for reduction
of Distal Embolization (GUARD) trial is also ongoing and will
determine the efficacy of this device in a study population
analogous to the SAFER trial. The appropriateness of contin-
uing such trials with a control arm without distal protection
has been a source of controversy. The use of the distal pro-
tection device reduces adverse events by 50% (the Per-
cuSurge device) and is approved for use and currently
available. As a result, the control arms of these trials are now
being reconsidered.
FilterWire EX™
The FilterWire EX (Boston Scientific, Natick, MA, USA) is
another filter device currently under clinical investigation
(Fig. 5). Similar to the AngioGuard, it is a low-profile
(<3.5 French) filter mounted on a 0.014 inch angioplasty wire
with pore holes of 80 microns that permit antegrade blood
flow while providing distal protection. The filter design is char-
acterized by an off-center position and ‘fish-mouth’ opening,
and can be retracted into any standard angioplasty balloon. A
radiopaque nitinol framework provides filter support and facili-
tates fluoroscopic visualization. Initial corporate reports of
feasibility, safety, and clinical efficacy are promising. A com-
plication rate of 7% was reported during 61 saphenous vein
graft interventions (4 non-Q wave MIs). This compares favor-
ably with historical control rates of >10%. Equally impressive,
unpublished results in small numbers of patients undergoing
carotid, native coronary artery, and renal percutaneous inter-
vention, will hopefully result in randomized, controlled clinical
trials to clarify these preliminary results.
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Figure 4
The AngioGuard guidewire filter device.
Figure 5
The FilterWire guidewire filter device and retrieval catheter.MedNova Neuroshield™
The MedNova NeuroShield (MedNova Inc., Galway, Ireland)
is a filter that is mounted on the distal tip of a 0.014 inch
guidewire, and its use requires both a delivery catheter and a
retrieval catheter. The filter contains a pre-shaped nitinol
expansion system that facilitates fluoroscopic visualization,
accurate deployment, and wall apposition. The filter
guidewire is placed within the delivery catheter and is passed
through the target stenosis, the delivery catheter is with-
drawn, the filter is deployed, and after completion of the vas-
cular intervention (angioplasty, stenting, etc.) the retrieval
catheter is used to envelop the filter. Then, the entire device
and its embolic contents are withdrawn.
Catheter Occlusion Devices
The Parodi Anti-Emboli System (PAES; ArteriA Medical
Science, Inc., San Francisco, CA, USA) is a guiding catheter
with an occlusion balloon attached at its distal end (Fig. 6).
The PAES establishes protection by reversing blood flow in
the target vessel [19,20]. In the carotid arteries, the system
works by occluding the common carotid, which creates a
negative pressure gradient distal to the balloon occlusion and
establishes retrograde flow in the internal carotid artery. The
external carotid is also occluded to avoid flow traveling from
the external one back up the internal one. This system estab-
lishes protection without the risk of disruption of the target
lesion, thereby reducing the risk of embolic stroke during
device deployment prior to percutaneous intervention.
The company reports performance of 200 cases worldwide
(in Italy, Argentina, New Zealand, Australia, Germany,
Belgium, France, and Sweden), with 100% successful
deployment and no ipsilateral embolic events. Two patients
suffered an intracranial hemorrhage, one patient died follow-
ing a periprocedural MI, one patient had a contralateral
embolic event during a coronary artery bypass graft proce-
dure performed at the same time, and one patient had a minor
contralateral ischemic stroke. A small Investigational Device
Exemption (IDE) clinical study in the US is planned.
Conclusion
There remains great controversy about the clinical signifi-
cance of the procedural infarctions that occur in approxi-
mately 10% of percutaneous interventions in the native
coronary arteries, and particularly the small subclinical infarc-
tions that occur during otherwise successful procedures.
There is nothing controversial or subtle, however, about a
great many of the embolic infarctions that occur during vein
graft or carotid interventions. Neither the approved device nor
the devices under investigation are, at present, perfect.
Doubtless all will undergo improvements in the future, and
offer hope for further increasing the safety of high-risk percu-
taneous interventions.
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The Parodi anti-embolization catheter.Available online http://cvm.controlled-trials.com/content/2/6/286
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
s
e
a
r
c
h
tion: First clinical experience using the PercuSurge Guard-
Wire system. J Endovasc Surg 1999, 6:321-331.
11. Liu MW, Douglas JS Jr, Lembo NJ, King SB 3rd: Angiographic
predictors of a rise in serum creatinine kinase (distal
embolization) after balloon angioplasty of saphenous vein
coronary artery bypass grafts. Am J Cardiol 1993, 72:514-517.
12. Jordan WD Jr, Voellinger DC, Doblar DD, Plyushcheva NP, Fisher
WS, McDowell HA: Microemboli detected by transcranial
Doppler monitoring in patients during carotid angioplasty
versus carotid endarterectomy. Cardiovasc Surg 1999, 7:33-
38.
13. Rapp JH, Pan XM, Sharp FR, Shah DM, Wille GA, Velez PM,
Troyer A, Higashida RT, Saloner D: Atheroemboli to the brain:
size threshold for causing acute neuronal cell death. J Vasc
Surg 2000, 32:68-76.
14. Ackerstaff RG, Moons KG, van de Vlasakker CJ, Moll FL, Ver-
meulen FE, Algra A, Spencer MP: Association of intraoperative
transcranial doppler monitoring variables with stroke from
carotid endarterectomy. Stroke 2000, 31:1817-1823.
15. Roubin GS, New G, Iyer SS, Vitek JJ, Al-Mubarak N, Liu MW,
Yadav J, Gomez C, Kuntz RE: Immediate and late clinical out-
comes of carotid artery stenting in patients with symptomatic
and asymptomatic carotid artery stenosis: a 5-year prospec-
tive analysis. Circulation 2001, 103:532-537.
16. Grube E, Webb J, for the SAFE study group: The SAFE study.
Multicenter evaluation of a protection catheter system for
distal embolization in coronary venous bypass grafts (SVG’s).
J Am Coll Cardiol 1999, 33:37A.
17. Baim DS. SAFER: A prospective, multi-center randomized trial
of distal protection in patients undergoing percutaneous
intervention of saphenous vein grafts. Presented at Tran-
scatheter Cardiovascular Therapeutics 2000. Washington, D.C.,
October 17-22, 2000.
18. Hobson RW II: Status of carotid angioplasty and stenting
trials. J Vasc Surg 1998, 27:791.
19. Ohki T, Parodi J, Veith FJ, Bates M, Bade M, Chang D, Mehta M,
Rabin J, Goldstein K, Harvey J, Lipsitz E: Efficacy of a proximal
occlusion catheter with reversal of flow in the prevention of
embolic events during carotid artery stenting: An experimen-
tal analysis. J Vasc Surg 2001, 33:504-509.
20. Parodi JC, La Mura R, Ferreira LM, Mendez MV, Cersosimo H,
Schonholz C, Garelli G: Initial evaluation of carotid angioplasty
and stenting with three different cerebral protection devices. J
Vasc Surg 2000, 32:1127-1136.